August 18, 2017 5:34 PM ET

Pharmaceuticals

Company Overview of Helsinn Therapeutics (U.S.), Inc.

Company Overview

Helsinn Therapeutics (U.S.), Inc. researches, develops, and manufactures pharmaceutical products for the treatment of a variety of cancer, gastrointestinal and metabolic conditions. The company was formerly known as Sapphire Therapeutics Inc. and changed its name to Helsinn Therapeutics (U.S.), Inc. in January, 2009. The company was founded in 2000 and is based in Iselin, New Jersey. As of January 28, 2009, Helsinn Therapeutics (U.S.), Inc. operates as a subsidiary of Helsinn Healthcare S.A.

170 Wood Avenue South

5th Floor

Iselin, NJ 08830

United States

Founded in 2000

Phone:

732-603-2800

Fax:

732-744-1088

Key Executives for Helsinn Therapeutics (U.S.), Inc.

Chief Executive Officer, President, and Director
Chief Medical Officer and Vice President
Age: 47
Compensation as of Fiscal Year 2017.

Helsinn Therapeutics (U.S.), Inc. Key Developments

Helsinn Therapeutics (U.S.), Inc. Presents at UBS Global Healthcare Conference 2017, May-23-2017 08:30 AM

Helsinn Therapeutics (U.S.), Inc. Presents at UBS Global Healthcare Conference 2017, May-23-2017 08:30 AM. Venue: Grand Hyatt New York, 109 E 42nd St., New York , NY 10017, United States. Speakers: William Mann, Chief Executive Officer, President, and Director.

Helsinn Therapeutics (U.S.), Inc. Presents at 9th Annual Conference Biotech Showcase, Jan-09-2017

Helsinn Therapeutics (U.S.), Inc. Presents at 9th Annual Conference Biotech Showcase, Jan-09-2017 . Venue: HILTON SAN FRANCISCO UNION SQUARE, 333 O'Farrell Street, San Francisco, CA 94102, United States.

Helsinn and Eisai Announce Revised US Collaboration for CINV Franchise

Helsinn and Eisai Inc. announced a revised agreement for their chemotherapy-induced nausea and vomiting (CINV) franchise. Under the new arrangement, Helsinn Therapeutics Inc., the U.S. affiliate of Helsinn, will obtain exclusive rights to promote and sell AKYNZEO (netupitant/palonosetron), its oral fixed dose combination product for the prevention of CINV. AKYNZEO had previously been co-promoted in the U.S. by both Helsinn and Eisai. As part of the revised agreement, Eisai and Helsinn will continue to co-promote ALOXI (palonosetron HCl) injection in the U.S. for CINV.

Similar Private Companies By Industry

Company Name Region
1st Order Pharmaceuticals, Inc. United States
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States
Bertelsmann AG Europe
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Helsinn Therapeutics (U.S.), Inc., please visit --. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.